meRfi®-GM
The Digital Textbook on Gut Microbiota and Beyond
Chemotherapy (CT)-induced gastrointestinal toxicity
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
40–80% of chemotherapy patients suffer from gastrointestinal toxicity. Intestinal damage caused by chemotherapy often requires adjustment of the dosage and duration of treatment, affecting effectiveness
Gastrointestinal toxicity includes epithelial death and damage and dysbiosis. Doxorubicin-induced acute dysbiosis correlates with epithelial apoptosis. Epithelial apoptosis drives acute disease and dys…
References (Sources)
- 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation
- Chemotherapy-driven dysbiosis in the intestinal microbiome.
- Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer
- Gastrointestinal toxicity of chemotherapeutic agents
- Metabolite-based inter-kingdom communication controls intestinal tissue recovery following chemotherapeutic injury
- The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis
- Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung